…
CNBX Pharmaceuticals Inc., a clinical-stage company, engages in the discovery, development, and commercialization of novel cannabinoid-based products and technologies for the treatment of cancer. Its lead product candidate is Cannabics SR, an oral capsule developed for the treatment of patients with advanced cancer and cancer anorexia cachexia syndrome. The company is also developing various drug candidates, including PLP-33 for the local treatment of lateral spreading, or sessile, colorectal polyps during colonoscopy, BRST-33 for the treatment of breast cancer, MLN-33 for the treatment of melanoma, and PRST-33 for the treatment of prostate cancer. In addition, it is developing RCC-33, an oral capsule containing a formulation of cannabinoids for the treatment of colorectal cancer. The company was formerly known as Cannabics Pharmaceuticals Inc. and changed its name to CNBX Pharmaceuticals Inc. in March 2022. CNBX Pharmaceuticals Inc. was incorporated in 2004 and is based in Bethesda, Maryland.
Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website
A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.
Cannabics Pharmaceuticals Inc develops cannabinoid-based therapeutics with a stated focus on oncology and personalized treatment approaches. Long-term growth drivers may include progress in clinical programs, regulatory acceptance of medical cannabis products, licensing or partnering opportunities, and wider clinical adoption of cannabinoid therapies. Investors may find exposure to a niche biotech pipeline attractive if programs advance and commercial pathways emerge.
Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.
| Breakdown | 2025-08-31 | 2024-08-31 | 2023-08-31 | 2022-08-31 | 2021-08-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-08-31 | 2024-08-31 | 2023-08-31 | 2022-08-31 | 2021-08-31 |
| Income before tax | -0.31M | -0.69M | -3.71M | -3.72M | -3.19M |
| Net income | -0.31M | -0.69M | -3.71M | -3.72M | -3.19M |
| Selling general administrative | 0.27M | 0.52M | 0.91M | 1.77M | 0.83M |
| Gross profit | - | 0.13M | - | - | - |
| Reconciled depreciation | 0.00M | 0.07M | 0.16M | 0.20M | 0.22M |
| Ebit | - | -0.68M | - | -2.95M | -2.60M |
| Ebitda | -0.27M | -0.60M | - | -3.52M | -2.97M |
| Depreciation and amortization | - | 0.07M | - | - | - |
| Operating income | -0.27M | -0.58M | -0.93M | -2.95M | -2.60M |
| Other operating expenses | 0.27M | 0.71M | - | - | - |
| Interest expense | 0.04M | 0.02M | 0.00M | 0.00M | 0.00M |
| Net interest income | -0.04M | -0.02M | -0.00M | -0.00M | -0.06M |
| Total revenue | 0.00M | 0.13M | 0.41M | 0.00M | 0.00M |
| Total operating expenses | 0.27M | 0.71M | 1.34M | 2.95M | 2.60M |
| Cost of revenue | - | 0.07M | - | - | - |
| Total other income expense net | -0.04M | -0.11M | -2.78M | -0.77M | -0.53M |
| Net income from continuing ops | -0.31M | -0.70M | -3.71M | -3.72M | -3.19M |
| Net income applicable to common shares | - | - | - | -3.72M | -3.19M |
| Breakdown | 2025-08-31 | 2024-08-31 | 2023-08-31 | 2022-08-31 | 2021-08-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-08-31 | 2024-08-31 | 2023-08-31 | 2022-08-31 | 2021-08-31 |
| Total assets | 0.02M | 0.03M | 0.50M | 0.81M | 3.08M |
| Other current assets | 0.00M | 0.00M | - | - | 0.20M |
| Total liab | 2.51M | 2.51M | 2.52M | 2.44M | 1.27M |
| Total stockholder equity | -2.50M | -2.48M | -2.02M | -1.63M | 1.81M |
| Other current liab | 1.27M | 2.47M | - | 0.22M | 0.22M |
| Common stock | 0.06M | 0.00M | - | 0.00M | 0.01M |
| Capital stock | 0.06M | - | 0.00M | 0.00M | 0.01M |
| Retained earnings | -25.27M | -24.95M | -24.26M | -20.55M | -16.83M |
| Other liab | - | - | - | 0.00M | - |
| Cash | 0.02M | 0.03M | 0.13M | 0.12M | 1.39M |
| Total current liabilities | 2.51M | 2.51M | 2.52M | 2.44M | 1.27M |
| Net debt | 1.18M | -0.03M | 1.21M | 1.64M | - |
| Short term debt | 1.20M | - | - | - | - |
| Short long term debt | 1.20M | - | 1.34M | 1.76M | 0.87M |
| Short long term debt total | 1.20M | 1.30M | - | - | - |
| Other stockholder equity | 22.72M | 22.47M | - | 0.88M | 1.55M |
| Property plant equipment | - | - | - | 0.44M | 0.64M |
| Total current assets | 0.02M | 0.03M | 0.22M | 0.20M | 1.59M |
| Long term investments | - | - | 0.00M | 0.18M | 0.85M |
| Net tangible assets | - | - | - | -1.63M | 1.81M |
| Net receivables | 0.00M | 0.00M | - | - | - |
| Accounts payable | 0.05M | 0.04M | 0.34M | 0.46M | 0.18M |
| Non current assets total | 0.00M | - | 0.27M | 0.61M | 1.49M |
| Breakdown | 2025-08-31 | 2024-08-31 | 2023-08-31 | 2022-08-31 | 2021-08-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-08-31 | 2024-08-31 | 2023-08-31 | 2022-08-31 | 2021-08-31 |
| Investments | - | 0.11M | 0.02M | 0.03M | 0.65M |
| Change to liabilities | - | - | - | 0.28M | -0.05M |
| Total cashflows from investing activities | - | 0.11M | - | 0.03M | 0.65M |
| Net borrowings | 0.16M | 0.03M | - | 0.39M | 2.46M |
| Total cash from financing activities | 0.16M | 0.03M | 0.10M | 0.39M | 2.46M |
| Net income | -0.31M | -0.70M | -3.71M | -3.72M | -3.19M |
| Change in cash | -0.01M | -0.10M | 0.01M | -1.26M | 0.61M |
| Begin period cash flow | 0.03M | 0.13M | 0.12M | 1.39M | 0.78M |
| End period cash flow | 0.02M | 0.03M | 0.13M | 0.12M | 1.39M |
| Total cash from operating activities | -0.17M | -0.24M | -0.11M | -1.68M | -2.49M |
| Depreciation | 0.00M | 0.07M | 0.16M | 0.20M | 0.22M |
| Other cashflows from investing activities | - | 0.11M | - | - | - |
| Change to account receivables | 0.00M | 0.09M | -0.01M | 0.12M | -0.01M |
| Other cashflows from financing activities | 0.16M | 0.03M | - | - | - |
| Change to netincome | - | - | - | 1.44M | 0.54M |
| Capital expenditures | 0.00M | 0.00M | 0.00M | 0.00M | 0.00M |
| Change in working capital | 0.10M | 0.13M | 0.47M | 0.41M | -0.06M |
| Stock based compensation | 0.00M | 0.14M | 0.18M | - | - |
| Other non cash items | 0.04M | 0.11M | 2.78M | 1.44M | 0.54M |
| Free cash flow | -0.17M | -0.25M | -0.11M | -1.68M | -2.49M |
Sector: Healthcare Industry: Biotechnology
|
Stock Name
|
Change
(USD) |
Price
(USD) |
Trailing
PE (x) |
Forward
PE (x) |
Price Sales
TTM (x) |
Price to Book Value (x)
|
Enterprise Value
to Revenue (x) |
Enterprise Value
to EBITDA (x) |
|---|---|---|---|---|---|---|---|---|
| CNBX Cannabics Pharmaceuticals Inc |
- -% |
0.00 | - | - | 0.90 | 20.39 | 6.29 | -0.49 |
| NVO Novo Nordisk A/S |
0.98 2.41% |
41.63 | 41.58 | 31.15 | 2.13 | 32.99 | 2.11 | 4.70 |
| VRTX Vertex Pharmaceuticals Inc |
-4.02 0.74% |
538.60 | 30.22 | 24.27 | 10.36 | 6.50 | 9.99 | 24.66 |
| REGN Regeneron Pharmaceuticals Inc |
4.28 0.45% |
955.47 | 29.07 | 20.12 | 7.57 | 3.82 | 6.95 | 19.42 |
| ARGNF argenx SE |
64.70 7.19% |
965.00 | 45.77 | 31.25 | 13.84 | 7.12 | 11.38 | 36.06 |
CNBX Pharmaceuticals Inc., a clinical-stage company, engages in the discovery, development, and commercialization of novel cannabinoid-based products and technologies for the treatment of cancer. Its lead product candidate is Cannabics SR, an oral capsule developed for the treatment of patients with advanced cancer and cancer anorexia cachexia syndrome. The company is also developing various drug candidates, including PLP-33 for the local treatment of lateral spreading, or sessile, colorectal polyps during colonoscopy, BRST-33 for the treatment of breast cancer, MLN-33 for the treatment of melanoma, and PRST-33 for the treatment of prostate cancer. In addition, it is developing RCC-33, an oral capsule containing a formulation of cannabinoids for the treatment of colorectal cancer. The company was formerly known as Cannabics Pharmaceuticals Inc. and changed its name to CNBX Pharmaceuticals Inc. in March 2022. CNBX Pharmaceuticals Inc. was incorporated in 2004 and is based in Bethesda, Maryland.
#3 Bethesda Metro Center, Bethesda, MD, United States, 20814
877 424 2429
1
| Name | Title | Year Born |
|---|---|---|
| Mr. Gabriel Yariv | Pres, COO & Exec. Chairman | 1976 |
| Mr. Eyal Barad | Co-Founder, CEO & Director | 1965 |
| Mr. Uri Ben-Or CPA, CPA, M.B.A., MBA | Chief Financial Officer | 1970 |
| Dr. Sanja Goldberg | Chief Technology Officer | 1976 |
| Noam Permont | VP of PR & Investor Relations | NA |
| Dr. Sigalit Ariely-Portnoy Ph.D. | Sr. Advisor of Regulation, Validation & Quality and Member of Advisory Board | 1964 |
| Dr. Tal Mofkadi Ph.D. | Financial Advisor & Member of Advisory Board | NA |
| Mr. Yasha Borstein | Chief Data Officer | 1963 |
| Dr. Yaakov Waksman | Head of Cannabidiol Research | 1952 |
| Dr. Ilya Reznik M.D. | Head of Neuropsychiatry Devel. | NA |
Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.